[PP.12.17] ANTIHYPERTENSIVE EFFICACY OF TRIPLE DRUGS FIXED COMBINATION THERAPY OF HIGH-RISK HYPERTENSIVE PATIENTS

Objective: Evaluate antihypertensive efficacy triple drugs fixed combination of indapamide, perindoprile and amlodipine in high-risk hypertensive patients during 12 weekly therapy. Design and method: The study included 22 high-risk hypertensive patients (II-III stage of essential hypertension, ESH/ESC 2013) who were resistant to bi-combination antihypertensive therapy, in average age 56.9 ± 9.2 years. All patients were administrated fixed combination of indapamide 1.7 ± 0.61 mg, perindoprile 6.54 ± 2.42 mg and amlodipine 6.81 ± 2.46 mg daily (Triplixam, “Servier”) within 12 weeks. Blood pressure (BP) measured by Korotkov method and 24-h ambulatory BP monitoring (ABPM) was performed. Results: By the end of the 12-weekly therapy was observed significantly reduce of systolic and diastolic BP (SBP and DBP) in both ambulatory and office measurements. During the therapy office SBP reduced on 23.4 ± 5.77% (from 165.95 ± 14.73 mmHg to 126.6 ± 7.92 mmHg, p = 0.0001), and DBP reduced on 21.37 ± 7.12% (from 101.36 ± 8.88 mmHg to 79.31 ± 5.83 mmHg, p = 0.0001). 86.4% of patients were achieved a target BP level <140/90 mmHg on office measurements. The results of 24-h ABPM shown normalization rates of 24-h BP, daytime BP and significantly reduce of nighttime BP. Thus, 24-h SBP reduced from 142.55 ± 12.9 mmHg to 128.61 ± 12.65 mmHg, p = 0.0001 and 24-h DBP from 88.0 ± 10.7 mmHg to 78.61 ± 8.43 mmHg, p = 0.002. High antihypertensive efficacy of triple drugs fixed combination characterized with significantly reduce high daily (24-h) BP variability from 18.35 ± 5.57 mmHg to 14.72 ± 3.71, p = 0.015 for SBP and from 13.86 ± 3.08 to 12.17 ± 2.4 mmHg, p = 0.043 for DBP. Conclusions: The results of our study have shown that 86.4% of high-risk hypertensive patients achieved BP goals with normalization of 24-h ABPM indexes such 24-h SBP, DBP and daily variability of SBP and DBP during 12-weekly therapy with Triplixam.

Перевод пока недоступен